AG
VIRX

Advisor Group’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

Advisor Group’s Portfolio VIRX Stock Details VIRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		$0 Hold
5
– – ﹤0.01% 5474
2019
Q3 		$0 Hold
5
– – ﹤0.01% 5458
2019
Q2 		$0 Buy
+5
New +$193 ﹤0.01% 5384

Other funds holding VIRX

ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
CC
Caxton Corporation Princeton, New Jersey $1.85M AUM 176.16% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Advisor Group's VIRX Position: Q4 2019 in Review

Advisor Group held its Viracta Therapeutics, Inc. Common Stock (VIRX) position steady in Q4 2019 at 5 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #5474.

Advisor Group first reported a position in VIRX in Q2 2019 and has held it in 3 quarters since. 44 funds tracked by Wall St. Rank hold VIRX as of Q4 2019.

  • Advisor Group held 5 shares of Viracta Therapeutics, Inc. Common Stock worth $0 as of Q4 2019.
  • Advisor Group left its Viracta Therapeutics, Inc. Common Stock share count unchanged in Q4 2019.
  • Viracta Therapeutics, Inc. Common Stock made up ﹤0.01% of Advisor Group's portfolio in Q4 2019, its #5474 holding.
  • Advisor Group first reported a position in Viracta Therapeutics, Inc. Common Stock in Q2 2019 and has held it in 3 quarters since.
  • 44 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q4 2019.

Based on Advisor Group's 13F filing for Q4 2019, filed 12 Feb 2020.